Research location
Cadillac
Michigan, United States
Advertisement
Research activity in Cadillac
Michigan, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 34 trials and 34 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Cadillac
34 linked trials · page 1 of 1Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)NCT03071692 · 2017-03-23 · 1 site observation
TERMINATED
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)NCT02465567 · 2015-06-30 · 1 site observation
COMPLETED
A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPDNCT02276222 · 2014-10-01 · 1 site observation
COMPLETED
A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk FactorsNCT02019264 · 2014-01-24 · 1 site observation
COMPLETED
Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular DiseaseNCT01609582 · 2012-06-01 · 1 site observation
TERMINATED
A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPDNCT01313650 · 2011-03-01 · 1 site observation
COMPLETED
Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseaseNCT01313676 · 2011-01-25 · 1 site observation
COMPLETED
Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes MedicationsNCT01107886 · 2010-05-01 · 1 site observation
COMPLETED
Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone AloneNCT01089790 · 2010-03-01 · 1 site observation
TERMINATED
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT01017952 · 2009-09-25 · 1 site observation
COMPLETED
Efficacy and Safety of Albiglutide in Treatment of Type 2 DiabetesNCT00838903 · 2009-02-01 · 1 site observation
COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 DiabetesNCT00838916 · 2009-02-01 · 1 site observation
COMPLETED
A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 DiabetesNCT00839527 · 2009-02-01 · 1 site observation
COMPLETED
A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.NCT00754988 · 2008-10-01 · 1 site observation
COMPLETED
Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or NaproxenNCT00346216 · 2006-10-04 · 1 site observation
COMPLETED
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)NCT00358436 · 2006-08-01 · 1 site observation
COMPLETED
Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.NCT00328627 · 2006-05-01 · 1 site observation
COMPLETED
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of HypertensionNCT00281593 · 2006-04-01 · 1 site observation
COMPLETED
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917NCT00290940 · 2006-01-01 · 1 site observation
COMPLETED
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)NCT00255645 · 2005-09-01 · 1 site observation
TERMINATED
Study of Muraglitazar Versus Pioglitazone in Type 2 DiabetesNCT00106808 · 2005-08-01 · 1 site observation
COMPLETED
A Phase II Study to Evaluate the Effects of Oral ONO-5129 in Type 2 Diabetes MellitusNCT00212641 · 2005-06-01 · 1 site observation
COMPLETED
Study of Co-administration of Olmesartan Medoxomil Plus Amlodipine in Patients With Mild to Severe HypertensionNCT00185133 · 2005-05-01 · 1 site observation
COMPLETED
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPDNCT00206167 · 2005-04-01 · 1 site observation
COMPLETED
GALLEX 9: Safety and Tolerability of Oral Tesaglitazar When Added to Insulin Therapy in Patients With Type 2 DiabetesNCT00229710 · 2005-02-01 · 1 site observation
TERMINATED
Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease)NCT00103922 · 2004-11-01 · 1 site observation
COMPLETED
Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard TherapyNCT00095134 · 2004-10-01 · 1 site observation
COMPLETED
GALLANT 9 Tesaglitazar vs. Placebo in Combination With InsulinNCT00242372 · 2004-08-01 · 1 site observation
TERMINATED
Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes MellitusNCT00762736 · 2004-07-01 · 1 site observation
COMPLETED
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.NCT00355342 · 2004-04-28 · 1 site observation
COMPLETED
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On InsulinNCT00329225 · 2002-09-01 · 1 site observation
COMPLETED
GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 DiabetesNCT00280865 · 2002-04-01 · 1 site observation
COMPLETED
Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD)NCT00665600 · 2002-02-01 · 1 site observation
COMPLETED
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT00268216 · 2000-09-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.